Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 6
Submit an article Journal homepage
312
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience

Nadjoua Maouchea Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKCorrespondence[email protected]
View further author information
,
Bhuvan Kishoreb Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKView further author information
,
Matthew W. Jennerc Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UKView further author information
,
Kevin Boydd Department of Haemato-Oncology, The Royal Marsden Hospital, Sutton, UKView further author information
,
Zara Bhattib Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKView further author information
,
Sarah Anne Birdd Department of Haemato-Oncology, The Royal Marsden Hospital, Sutton, UKView further author information
,
Gurvin Chanderb Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKView further author information
,
Rebecca Robinsonb Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKView further author information
,
Grant D. Vallancea Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKView further author information
,
Mark Offere Department of Haematology, Frimley Health NHS Foundation Trust, Frimley, UKView further author information
,
Jaimal Kotharia Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKView further author information
,
Andy Peniketa Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKView further author information
,
Robin Aitchisonf Department of Haematology, Buckinghamshire Healthcare NHS Trust, Bucks, UKView further author information
,
Moez Dungarwallag Department of Haematology, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UKView further author information
,
Freya Collingsh Department of Haematology, Great Western Hospitals NHS Foundation Trust, Swindon, UKView further author information
,
Ceri Bygravei Department of Haematology, University Hospital of Wales, Cardiff, UKView further author information
&
Karthik Ramasamya Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKView further author information
 show all
Pages 1396-1404 | Received 09 Aug 2020, Accepted 09 Dec 2020, Published online: 25 Dec 2020

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Mehmet Bakırtaş, Mehmet Sinan Dal, Tuğçe Nur Yiğenoğlu, Asli Odabası Giden, Istemi Serin, Semih Başcı, Yasin Kalpakci, Serdal Korkmaz, Omer Ekinci, Murat Albayrak, Abdulkadir Basturk, Duzgun Ozatli, Mehmet Hilmi Dogu, Tuba Hacıbekiroglu, Merih Kızıl Çakar, Turgay Ulas, Mine Miskioglu, Emine Gulturk, Bulent Eser & Fevzi Altuntas. (2023) Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey. Journal of Chemotherapy 0:0, pages 1-7.
Read now

Articles from other publishers (2)

Ji Hyun Lee, Sung-Hyun Kim, Hye Ryeon Kim, Chang-Ki Min, Je-Jung Lee, Ho-Jin Shin, Jae-Cheol Jo, Ji Yun Lee, Joon Ho Moon & Kihyun Kim. (2022) Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma. International Journal of Hematology 117:2, pages 225-235.
Crossref
Shansa Pranami E. Jayaweera, Sacheela Prasadi Wanigasinghe Kanakanamge, Dharshika Rajalingam & Gayathri N. Silva. (2021) Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. Frontiers in Oncology 11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.